Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Teratogenicity01:07

Teratogenicity

4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

1.8K
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
1.8K
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

229
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

1.4K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.4K
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

229
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
229

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between ambient air pollution and colorectal cancer risk: The Multiethnic Cohort Study.

Environmental research·2026
Same author

Untargeted serum metabolomics and air pollution in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Traffic-related air toxics and Parkinson's disease in California's Central Valley.

The Science of the total environment·2026
Same author

Integration of the serum metabolome and gut microbiome underscores the importance of altered lipid metabolism and potential immune modulation in Parkinson's Disease.

Brain disorders (Amsterdam, Netherlands)·2026
Same author

Grandmother's pregnancy complications and autism spectrum disorders in grandchildren, a California multigenerational cohort study.

JCPP advances·2026
Same author

Maternal Thyroid Diseases, Medication Use and Childhood Cancer Risks in Offspring: A Population-Based Cohort Study in Denmark.

International journal of cancer·2026

Related Experiment Video

Updated: May 2, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

90.5K

Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders.

Zeyan Liew1, Beate Ritz2, Cristina Rebordosa3

  • 1Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles.

JAMA Pediatrics
|February 26, 2014
PubMed
Summary

Maternal use of acetaminophen during pregnancy is linked to an increased risk of attention-deficit/hyperactivity disorder (ADHD)-like behaviors and hyperkinetic disorders (HKDs) in children. These findings highlight potential public health concerns regarding common medication use in pregnancy.

More Related Videos

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

813
Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
15:27

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

14.3K

Related Experiment Videos

Last Updated: May 2, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

90.5K
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

813
Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
15:27

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

14.3K

Area of Science:

  • Obstetrics and Gynecology
  • Pediatrics
  • Neuroscience
  • Public Health

Background:

  • Acetaminophen (paracetamol) is a widely used analgesic and antipyretic during pregnancy.
  • Emerging research suggests acetaminophen may act as a hormone disruptor, potentially impacting fetal neurodevelopment.
  • Prenatal exposure to certain substances can influence a child's long-term behavioral outcomes.

Purpose of the Study:

  • To investigate the association between prenatal acetaminophen exposure and the risk of attention-deficit/hyperactivity disorder (ADHD)-like behaviors and hyperkinetic disorders (HKDs) in children.
  • To determine if increased acetaminophen use during gestation correlates with a higher incidence of these neurodevelopmental outcomes.
  • To assess potential confounding factors, such as maternal health and infections, in the observed associations.

Main Methods:

  • A prospective cohort study involving 64,322 mother-child pairs from the Danish National Birth Cohort (1996-2002).
  • Acetaminophen exposure during pregnancy was prospectively assessed via telephone interviews.
  • Outcomes included parental reports of behavioral problems (age 7), diagnosed hyperkinetic disorders (HKDs), and ADHD medication prescriptions, ascertained through national registries.

Main Results:

  • Maternal acetaminophen use during pregnancy was associated with a significantly higher risk of HKD diagnosis (HR=1.37), ADHD medication use (HR=1.29), and ADHD-like behaviors (RR=1.13).
  • A dose-response relationship was observed, with increased frequency and duration of acetaminophen use during pregnancy showing stronger associations with all outcomes.
  • These associations remained significant after adjusting for potential confounders, including maternal inflammation, infection, and mental health issues.

Conclusions:

  • Prenatal exposure to acetaminophen is associated with an elevated risk of hyperkinetic disorders and ADHD-like behaviors in offspring.
  • Given the high prevalence of both acetaminophen use in pregnancy and these behavioral outcomes, the findings have significant public health implications.
  • Further research is warranted to elucidate the mechanisms underlying this association and to inform clinical guidelines.